New Delhi: The Pharmaceuticals Export Promotion Council of India (Pharmexcil) announces a period of robust growth in pharmaceutical exports in the month of May. India’s pharmaceutical export industry continued its growth trajectory in May 2025, reaching USD 4,961.71 million.
This represents a 7.38% expansion compared to May 2024-25. This growth is a testament to Pharmexcil’s efforts in spearheading a transformative period for India’s pharmaceutical sector, moving beyond its ‘Pharmacy of the World’ reputation to embrace cutting-edge sustainable manufacturing, expand its global market presence, and streamline regulatory processes through digital innovation.
These strategic initiatives underpin the nation’s ambitious goal of achieving a trillion-dollar trade target for the pharmaceutical sector.
Robust Export and Import Performance in May 2025 –
-
Formulations and biologicals continue to hold the major share of India’s total exports accounting for 75.74%during this period.
-
The second major category by value is Bulk drugs and drug intermediates. During May 2025-26 this segment expanded by 4.40%.
-
Vaccines were the third largest exported category, valued at USD 190.13 million, experiencing a significant 13.64% increase.
-
Surgicals grew by 8.58%, reaching USD 124.62 million.
-
Ayush & Herbals products saw a 7.36% growth, with a value of USD 119.89 million.
-
NAFTA, EUROPE, AFRICA and LAC are our four major regions for pharma exports. These four regions together account for 76% of our total exports.
-
ASEAN (4.88%) was a newly contracted region during this period.
-
India’s top 5 countries for pharma exports during May 2025-26 were USA, UK, Brazil, South Africa, and France.
-
Exports to USA, which account for 34.50% of our exports in pharma products, have expanded by 1.50%. Our exports to the USA were valued at USD 1711.75 million during May 2025-26.
-
Europe grew moderately by 3.14%, and Africa by 1.71%.
